News

New research presented at the American College of Rheumatology’s Annual Meeting in Boston claims that end-stage lung disease patients with diseases like Scleroderma should not be denied the opportunity of receiving a lung transplant because of extra-pulmonary factors and, consequently, short- and long-term survival concerns. The…

November 18th has been officially named chronic thromboembolic pulmonary hypertension (CTEPH) Awareness Day. This will be the first ever awareness day dedicated specifically to CTEPH. Chronic thromboembolic pulmonary hypertension is caused by chronic blood clots in the lungs that cause pressure in the pulmonary arteries and the right side…

Photo of Roseanne Huber from http://phadailybeat.blogspot.pt The Pulmonary Hypertension Association recently reached out to running enthusiast and pulmonary hypertension patient Roseanne Huber from Florida to share her insightful story of taking control of her condition. Huber was diagnosed with the life-threatening disease in 2006…

Although riociguat is indicated for treatment of pulmonary hypertension, Bayer HealthCare is looking to repurpose the drug to treat patients with diffuse cutaneous systemic sclerosis (dcSSc). Bayer initiated a randomized, double-blind, placebo-controlled phase 2 study using riociguat in patients with the…

Members of the Pulmonary Hypertension Association (PHA) accompanied PH patients from across the country yesterday to meet with Members of Congress. November is Pulmonary Hypertension Awareness Month, and to boost support for national efforts against this life threatening cardiopulmonary disease, they discussed the everyday plight…

The American Heart Association’s (AHA) journal Circulation has announced plans for a new thematic series on the recent advances in diagnosing and treating Pulmonary Hypertension (PH), in which an expert research team will present progress made in the research field for the disease. The topics in the series include patient…

In a recent review published in Circulation, the official Journal of the American Heart Association, Jonathan and Stuart Rich examined the current status of the epidemiology, prognosis, and update of the clinical classification for PH. In the review, the authors mainly focus on the diagnostic approach of suspected Pulmonary Hypertension…

Last week, in a bold move to call for support of a rare and debilitating pulmonary disease, the Pulmonary Hypertension Association was featured on the largest screen in the world — the NASDAQ Tower on Times Square, just after ringing the opening bell for the opening of the…

In a recent study entitled “Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension” the authors report that phase-contrast magnetic resonance (MR) imaging is an accurate method for diagnosing pulmonary hypertension by estimating increased mean pulmonary arterial pressure. The study…

A live webinar exploring the development of Pulmonary Fibrosis in Scleroderma patients will be hosted by Dr. Paul Wolters, Director of Biological Research at the Interstitial Lung Disease Program at University of California San Francisco (UCSF), on Thursday, November 13, 2014 at 10:00 a.m. PST. The presentation is called “Emerging Therapies in…

Patients with systemic sclerosis hoping to enroll in clinical trials investigating hematopoietic stem cell transplantation may be disqualified if they have pulmonary hypertension. During the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, reasons for turning away interested patients included pulmonary hypertension and left ventricular ejection fraction less than…

In a perfect world, equivalent responses to treatments from patients with pulmonary hypertension would make all treatment outcomes predictable and highly effective. In reality, this is not the case. However, distinguishing subtypes of pulmonary arterial hypertension can at least improve treatment outcomes by better matching patients to treatments using…